Portland, Ore. (November 18, 2019)— The National Psoriasis Foundation, NPF, has established two new funding opportunities for 2020 focused on advancing research related to prevention and milestones toward a cure for psoriatic disease.

Inspired by the National Institute of Health Accelerating Medicines Partnership (AMP), NPF will invest an estimated $6.5 million over five years to establish the Psoriasis Prevention Initiative (PPI). Aiming to identify an intervention that will prevent the onset of psoriatic disease, disease relapse or relevant comorbidities, the PPI grant focuses on multi-institution, multi-disciplinary, team-based research.

“Funding for PPI is very different from our other grants as the intention is to create an opportunity for the research and clinical communities to combine their perspectives to accelerate psoriatic disease research efforts,” said Randy Beranek, president, and CEO, NPF. “We are uniquely positioned to do this and feel that supporting a collaborative effort will improve the prospect for success in finding a prevention for psoriatic disease.”

PPI letters of intent are being accepted now until December 13, 2019, with priority given to proposals based on their ability to:

• Establish or develop innovative collaborations among basic, translational, and clinical researchers.
• Identify a multi-faceted, multi-disciplinary, multi-institutional collaborative team and research approach.
• Explain how their approach will have the highest likelihood of developing an intervention that will prevent the onset of psoriatic disease, the onset of relapse, or the onset of related comorbidities.

Proposals that have the potential to achieve significant progress toward its aspirational goal within five years and will occur in three phases:

• Year One: One to two grants will be awarded funds up to $250,000.
• Year Two: Upon demonstration of progress and promising future potential, one grantee will be awarded funds up to $1,500,000.
• Years Three-Five: Upon continued, demonstration of progress the grantee has the opportunity to renew their proposal for up to $1,500,000 annually for an additional three years of funding.

NPF has also launched the Milestones to a Cure grant which aims to support psoriatic disease research focused on treatment durability, remission/relapse, prevention, and personalized medicine. Grants will be for a one-year term and up to $100,000 will be awarded. Proposals are being accepted now until January 13, 2020.

To learn more details and deadlines for each grant, as well as all NPF grant offerings, visit www.psoriasis.org/grants.